文献速递间质性肺疾病

达雷妥尤单抗成功挽救MDA5阳性皮肌炎相关快速进展间质性肺病一例

Successful Rescue Therapy With Daratumumab in Rapidly Progressive Interstitial Lung Disease Caused by MDA5-Positive Dermatomyositis.
PubMed 文献 · Chest · 2023-01-01

本病例报告描述一名19岁男性MDA5阳性皮肌炎患者,在多种免疫抑制治疗(激素、IVIG、托法替布、环磷酰胺、霉酚酸酯、环孢素、利妥昔单抗)后仍出现呼吸衰竭的快速进展间质性肺病。启用抗CD38抗体达雷妥尤单抗挽救治疗,每周1800 mg连续4次注射后肺部显著改善。随访6个月病情稳定缓解,CD38+浆细胞持续耗竭且MDA5抗体滴度持续下降;此为达雷妥尤单抗治疗皮肌炎的首例成功报告。

要点

  • MDA5阳性皮肌炎可并发危及生命的快速进展间质性肺病。
  • 多种免疫抑制治疗失败后,达雷妥尤单抗挽救治疗可显著改善肺部病变。
  • CD38靶向治疗可能对严重抗体介导的自身免疫病具有潜力。

核心结论

  • 达雷妥尤单抗在多种免疫抑制治疗失败的MDA5阳性皮肌炎相关快速进展间质性肺病中实现成功挽救治疗。
  • 该病例为达雷妥尤单抗治疗皮肌炎的首例成功报告,提示CD38靶向治疗对严重抗体介导自身免疫病的潜力。

研究设计与样本

  • 单个病例报告:一名19岁男性MDA5阳性皮肌炎患者,表现为快速进展间质性肺病并导致呼吸衰竭。

主要发现

  • 患者在多种免疫抑制治疗(激素、IVIG、托法替布、环磷酰胺、霉酚酸酯、环孢素、利妥昔单抗)后仍出现呼吸衰竭。
  • 启用达雷妥尤单抗挽救治疗,每周1800 mg连续4次注射后观察到肺部显著改善。
  • 随访6个月病情稳定缓解,肺部显著改善,CD38+浆细胞持续耗竭且MDA5抗体滴度持续下降。

关键数值与推荐

  • 达雷妥尤单抗给药方案:每周1800 mg,共4次注射。
  • 随访6个月时观察到稳定疾病缓解、肺部显著改善、CD38+浆细胞持续耗竭及MDA5抗体滴度持续下降。

临床怎么用

  • 对于多种免疫抑制治疗失败的MDA5阳性皮肌炎相关快速进展间质性肺病,可考虑达雷妥尤单抗作为挽救治疗选择。

局限性

  • 为单个病例报告,结论的外推需更多研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Melanoma differentiation-associated gene 5 (MDA5) positive dermatomyositis is a rare systemic autoimmune disease that is associated with life-threatening rapidly progressive interstitial lung disease. We report the case of a 19-year-old male patient with a life-threatening disease course caused by rapidly progressive interstitial lung disease that caused respiratory failure despite intensive immunosuppression with multiple agents (steroids, IV immunoglobulins, tofacitinib, cyclophosphamide, mycophenolate mofetil, ciclosporin and rituximab). Rescue therapy with daratumumab, an anti-CD38-antibody, was initiated. Significant pulmonary improvement was noticed after 4 weekly injections of 1,800 mg. After 6 months of follow up, stable disease remission with significant pulmonary improvement and persistent depletion of CD38+ plasma cells and MDA5-antibody titers were seen. This is the first report of the successful use of daratumumab in dermatomyositis. It highlights the potential of CD38 targeted therapies for severe antibody-mediated autoimmune diseases such as dermatomyositis.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Holzer MT, Nies JF, Oqueka T, et al. Successful Rescue Therapy With Daratumumab in Rapidly Progressive Interstitial Lung Disease Caused by MDA5-Positive Dermatomyositis. Chest. 2023. PMID: 36628678. doi:10.1016/j.chest.2022.08.2209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。